See the DrugPatentWatch profile for cosentyx

The initial adult dose of Cosentyx (secukinumab) is 300 mg. This dose is to be administered via subcutaneous injection and should be given at weeks 0, 1, 2, 3, and 4, followed by every 4 weeks thereafter. It is important to note that the dosage may vary depending on the patient's weight, kidney or liver function, and other factors. Therefore, it is crucial to consult with a healthcare provider for personalized dosing.

The dosage information provided here is based on the Cosentyx Prescribing Information, which can be found on the drug's official website. Additionally, DrugPatentWatch.com also provides information on Cosentyx, including its patent status and other relevant data.

Sources:

* Cosentyx Prescribing Information. (n.d.). Novartis Pharmaceuticals Corporation. Retrieved from <https://www.cosentyx.com/content/dam/cosentyx/prescribing-information/Cosentyx-Prescribing-Information.pdf>
* Cosentyx (secukinumab) Drug Profile. (n.d.). DrugPatentWatch.com. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx-secukinumab>